Symbols / TLSI Stock $4.64 +0.22% TriSalus Life Sciences, Inc.

Healthcare • Medical Devices • United States • NGM
TLSI (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Medical Devices
CEO Ms. Mary T. Szela B.S.N., M.B.A.
Exch · Country NGM · United States
Market Cap 284.96M
Enterprise Value 298.46M
Income -69.69M
Sales 45.15M
FCF (ttm) -8.76M
Book/sh -0.68
Cash/sh 0.33
Employees 102
Insider 10d —
IPO Feb 08, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -18.56
PEG —
P/S 6.31
P/B -6.85
P/C —
EV/EBITDA -11.34
EV/Sales 6.61
Quick Ratio 2.35
Current Ratio 2.80
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -1.84
EPS next Y -0.25
EPS Growth —
Revenue Growth 59.80%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-07
Earnings (prior) 2026-03-05
ROA -56.80%
ROE —
ROIC —
Gross Margin 84.57%
Oper. Margin -24.77%
Profit Margin -86.88%
Shs Outstand 61.41M
Shs Float 51.51M
Insider Own 28.21%
Instit Own 21.06%
Short Float 2.85%
Short Ratio 7.34
Short Interest 1.32M
52W High 7.95
vs 52W High -41.64%
52W Low 3.42
vs 52W Low 35.67%
Beta 0.54
Impl. Vol. —
Rel Volume 0.27
Avg Volume 180.78K
Volume 49.47K
Target (mean) $9.20
Tgt Median $10.00
Tgt Low $7.00
Tgt High $11.00
# Analysts 5
Recom Strong_buy
Prev Close $4.63
Price $4.64
Change 0.22%
About

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$9.20
Mean price target
2. Current target
$4.64
Latest analyst target
3. DCF / Fair value
$-2.57
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.64
Low
$7.00
High
$11.00
Mean
$9.20

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-09 main Canaccord Genuity Buy → Buy $7
2026-03-06 main Canaccord Genuity Buy → Buy $7
2025-12-17 main Canaccord Genuity Buy → Buy $12
2025-03-28 main Canaccord Genuity Buy → Buy $11
2025-02-13 init Lake Street — → Buy $10
2025-01-24 reit Roth MKM Buy → Buy $11
2024-12-17 init Cantor Fitzgerald — → Overweight $10
2024-11-15 main Canaccord Genuity Buy → Buy $11
2024-11-11 init Roth MKM — → Buy $11
2024-10-25 init Northland Capital Markets — → Outperform $13
2024-09-16 init Oppenheimer — → Outperform $10
2024-06-27 main Canaccord Genuity Buy → Buy $12
2024-05-30 init Canaccord Genuity — → Buy $12
2024-05-10 init JonesTrading — → Buy $16
News
RSS: Latest TLSI news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-17 SZELA MARY T. Chief Executive Officer — 20,302 $3.85 $79,383
2026-03-16 STEVENS JENNIFER Officer — 3,530 $4.09 $14,509
2026-03-16 MARSHAK RICHARD Officer — 3,457 $4.09 $14,210
2026-03-16 COX BRYAN F Officer — 3,184 $4.09 $13,085
2026-03-16 DEVLIN JODI Officer — 3,207 $4.09 $13,171
2026-02-23 SZELA MARY T. Chief Executive Officer — 30,487 $5.45 $166,154
2026-02-23 GORDON GARY B Director — 9,756 $5.45 $53,170
2026-02-23 PATIENCE DAVID Chief Financial Officer — 3,657 $5.45 $19,931
2026-02-23 VALLE WILLIAM J. Director — 30,487 $5.45 $166,154
2026-02-23 STANSKY MICHAEL P. CPA Director — 361,098 $5.45 $1,967,984
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
45.15
+53.41%
29.43
+58.99%
18.51
+49.31%
12.40
Operating Revenue
45.15
+53.41%
29.43
+58.99%
18.51
+49.31%
12.40
Cost Of Revenue
6.96
+69.75%
4.10
+57.50%
2.60
+15.37%
2.26
Reconciled Cost Of Revenue
6.96
+69.75%
4.10
+57.50%
2.60
+15.37%
2.26
Gross Profit
38.19
+50.77%
25.33
+59.24%
15.91
+56.86%
10.14
Operating Expense
65.13
+5.92%
61.49
-12.63%
70.38
+51.10%
46.58
Research And Development
14.96
-15.39%
17.69
-40.71%
29.84
+39.69%
21.36
Selling General And Administration
50.17
+14.52%
43.80
+8.04%
40.55
+60.76%
25.22
Selling And Marketing Expense
28.71
+11.11%
25.84
+51.69%
17.03
+33.73%
12.74
General And Administrative Expense
21.46
+19.44%
17.97
-23.59%
23.51
+88.35%
12.48
Other Gand A
21.46
+19.44%
17.97
-23.59%
23.51
+88.35%
12.48
Total Expenses
72.10
+9.91%
65.60
-10.13%
72.99
+49.45%
48.84
Operating Income
-26.95
+25.49%
-36.16
+33.61%
-54.48
-49.50%
-36.44
Total Operating Income As Reported
-26.95
+25.49%
-36.16
+33.61%
-54.48
-49.50%
-36.44
EBITDA
-33.05
-26.12%
-26.20
+55.32%
-58.65
-25.39%
-46.78
Normalized EBITDA
-26.22
+25.78%
-35.33
+40.74%
-59.61
-33.68%
-44.59
Reconciled Depreciation
0.63
-15.86%
0.74
+8.77%
0.68
+71.86%
0.40
EBIT
-33.68
-24.96%
-26.95
+54.58%
-59.34
-25.78%
-47.18
Total Unusual Items
-6.83
-174.85%
9.12
+852.40%
0.96
+143.82%
-2.19
Total Unusual Items Excluding Goodwill
-6.83
-174.85%
9.12
+852.40%
0.96
+143.82%
-2.19
Special Income Charges
-2.74
-124.42%
11.23
-4.93%
11.81
0.00
Other Special Charges
—
—
-1.52
-118.29%
8.31
Restructuring And Mergern Acquisition
2.74
+124.42%
-11.23
-9.11%
-10.29
0.00
Net Income
-39.23
-30.56%
-30.05
+49.39%
-59.36
-25.80%
-47.19
Pretax Income
-39.22
-30.56%
-30.04
+49.39%
-59.35
-25.81%
-47.18
Net Non Operating Interest Income Expense
-4.99
-85.74%
-2.69
-747.23%
0.41
+131.84%
0.18
Interest Expense Non Operating
5.54
+79.42%
3.09
+19212.50%
0.02
+1500.00%
0.00
Net Interest Income
-4.99
-85.74%
-2.69
-747.23%
0.41
+131.84%
0.18
Interest Expense
5.54
+79.42%
3.09
+19212.50%
0.02
+1500.00%
0.00
Interest Income Non Operating
0.56
+37.38%
0.40
-6.26%
0.43
+139.44%
0.18
Interest Income
0.56
+37.38%
0.40
-6.26%
0.43
+139.44%
0.18
Other Income Expense
-7.29
-182.67%
8.81
+266.45%
-5.29
+51.51%
-10.92
Other Non Operating Income Expenses
-0.46
-46.15%
-0.31
+95.01%
-6.25
+28.40%
-8.73
Gain On Sale Of Security
-4.09
-93.93%
-2.11
+80.59%
-10.86
-396.57%
-2.19
Tax Provision
0.01
+16.67%
0.01
-33.33%
0.01
+0.00%
0.01
Tax Rate For Calcs
0.00
0.00
0.00
-100.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
+100.00%
-0.46
Net Income Including Noncontrolling Interests
-39.23
-30.56%
-30.05
+49.39%
-59.36
-25.80%
-47.19
Net Income From Continuing Operation Net Minority Interest
-39.23
-30.56%
-30.05
+49.39%
-59.36
-25.80%
-47.19
Net Income From Continuing And Discontinued Operation
-39.23
-30.56%
-30.05
+49.39%
-59.36
-25.80%
-47.19
Net Income Continuous Operations
-39.23
-30.56%
-30.05
+49.39%
-59.36
-25.80%
-47.19
Normalized Income
-32.40
+17.29%
-39.17
+35.07%
-60.32
-32.69%
-45.46
Net Income Common Stockholders
-69.69
-109.70%
-33.23
+47.75%
-63.60
-27.16%
-50.02
Otherunder Preferred Stock Dividend
30.46
0.00
-100.00%
2.98
+5.37%
2.83
Diluted EPS
—
-1.31
+80.53%
-6.73
+95.83%
-161.55
Basic EPS
—
-1.31
+80.53%
-6.73
+95.83%
-161.55
Basic Average Shares
—
25.33
+169.61%
9.40
+2934.71%
0.31
Diluted Average Shares
—
25.33
+169.61%
9.40
+2934.71%
0.31
Diluted NI Availto Com Stockholders
-69.69
-109.70%
-33.23
+47.75%
-63.60
-27.16%
-50.02
Preferred Stock Dividends
—
3.19
+153.42%
1.26
-55.53%
2.83
Line Item Trend 2023-12-31
Total Assets
24.60
Current Assets
20.86
Cash Cash Equivalents And Short Term Investments
11.78
Cash And Cash Equivalents
11.78
Receivables
3.55
Accounts Receivable
3.55
Inventory
2.54
Raw Materials
0.61
Finished Goods
2.06
Prepaid Assets
2.99
Total Non Current Assets
3.74
Net PPE
3.27
Gross PPE
6.36
Accumulated Depreciation
-3.09
Properties
0.00
Machinery Furniture Equipment
3.80
Construction In Progress
0.60
Other Properties
1.19
Leases
0.77
Goodwill And Other Intangible Assets
1.13
Other Non Current Assets
0.47
Total Liabilities Net Minority Interest
51.66
Current Liabilities
14.69
Payables And Accrued Expenses
9.88
Payables
3.42
Accounts Payable
3.39
Current Accrued Expenses
6.46
Pensionand Other Post Retirement Benefit Plans Current
4.06
Total Tax Payable
0.03
Current Debt And Capital Lease Obligation
0.35
Current Capital Lease Obligation
0.35
Other Current Liabilities
0.39
Total Non Current Liabilities Net Minority Interest
36.98
Long Term Debt And Capital Lease Obligation
1.24
Long Term Debt
—
Long Term Capital Lease Obligation
1.24
Other Non Current Liabilities
35.73
Preferred Securities Outside Stock Equity
0.00
Stockholders Equity
-27.07
Common Stock Equity
-27.07
Capital Stock
0.00
Common Stock
0.00
Preferred Stock
0.00
Share Issued
26.41
Ordinary Shares Number
26.41
Treasury Shares Number
0.00
Additional Paid In Capital
222.44
Retained Earnings
-249.50
Total Equity Gross Minority Interest
-27.07
Total Capitalization
-27.07
Working Capital
6.17
Invested Capital
-27.07
Total Debt
1.59
Net Debt
—
Capital Lease Obligations
1.59
Net Tangible Assets
-27.07
Tangible Book Value
-27.07
Derivative Product Liabilities
—
Inventories Adjustments Allowances
-0.12
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-18.01
+55.90%
-40.84
+19.25%
-50.58
-56.53%
-32.31
Cash Flow From Continuing Operating Activities
-18.01
+55.90%
-40.84
+19.25%
-50.58
-56.53%
-32.31
Net Income From Continuing Operations
-39.23
-30.56%
-30.05
+49.39%
-59.36
-25.80%
-47.19
Depreciation Amortization Depletion
0.63
-15.86%
0.74
+8.77%
0.68
+71.86%
0.40
Depreciation
0.63
-15.86%
0.74
+8.77%
0.68
+147.83%
0.28
Amortization Cash Flow
—
—
0.02
-85.25%
0.12
Depreciation And Amortization
0.63
-15.86%
0.74
+8.77%
0.68
+71.86%
0.40
Amortization Of Intangibles
—
—
0.02
-85.25%
0.12
Other Non Cash Items
5.02
+151.49%
-9.75
-203.11%
-3.22
-134.55%
9.31
Stock Based Compensation
9.13
+67.82%
5.44
+288.09%
1.40
+280.98%
0.37
Provisionand Write Offof Assets
0.16
-12.83%
0.19
0.00
—
Asset Impairment Charge
—
—
0.19
0.00
Operating Gains Losses
4.21
+97.46%
2.13
-77.29%
9.38
+275.76%
2.50
Gain Loss On Investment Securities
4.09
+93.93%
2.11
-80.59%
10.86
+396.57%
2.19
Gain Loss On Sale Of PPE
0.12
+421.74%
0.02
-47.73%
0.04
-85.81%
0.31
Change In Working Capital
2.07
+121.66%
-9.55
-1878.21%
0.54
-76.65%
2.30
Change In Receivables
-1.63
+4.94%
-1.72
+13.14%
-1.98
-889.50%
-0.20
Changes In Account Receivables
-1.63
+4.94%
-1.72
+13.14%
-1.98
-889.50%
-0.20
Change In Inventory
0.97
+164.60%
-1.50
-40.07%
-1.07
-499.44%
-0.18
Change In Prepaid Assets
0.84
+150.75%
-1.67
-261.34%
1.03
+139.81%
-2.59
Change In Payables And Accrued Expense
2.02
+146.08%
-4.38
-254.47%
2.84
-45.90%
5.25
Change In Payable
—
-4.38
-254.47%
2.84
-45.90%
5.25
Change In Account Payable
—
-4.38
-254.47%
2.84
-45.90%
5.25
Change In Other Current Assets
—
—
0.20
+80.36%
0.11
Change In Other Current Liabilities
-0.13
+51.80%
-0.28
+1.07%
-0.28
-222.99%
-0.09
Investing Cash Flow
-0.84
-142.90%
-0.34
+78.27%
-1.59
+11.09%
-1.79
Cash Flow From Continuing Investing Activities
-0.84
-142.90%
-0.34
+78.27%
-1.59
+11.09%
-1.79
Net PPE Purchase And Sale
-0.84
-142.90%
-0.34
+41.33%
-0.59
+10.23%
-0.66
Purchase Of PPE
-0.92
-166.09%
-0.34
+41.33%
-0.59
+10.23%
-0.66
Sale Of PPE
0.08
0.00
—
—
Capital Expenditure
-0.92
-166.09%
-0.34
+41.33%
-0.59
+25.19%
-0.79
Net Intangibles Purchase And Sale
—
—
-0.53
-306.87%
-0.13
Purchase Of Intangibles
—
—
-0.53
-306.87%
-0.13
Net Other Investing Changes
—
—
-1.00
+0.00%
-1.00
Financing Cash Flow
30.76
-18.91%
37.94
-30.56%
54.63
+305.80%
13.46
Cash Flow From Continuing Financing Activities
30.76
-18.91%
37.94
-30.56%
54.63
+305.80%
13.46
Net Issuance Payments Of Debt
9.92
-60.19%
24.92
+28739.08%
-0.09
+33.59%
-0.13
Issuance Of Debt
10.00
-60.00%
25.00
0.00
0.00
Repayment Of Debt
-0.08
+3.57%
-0.08
+3.45%
-0.09
+33.59%
-0.13
Long Term Debt Issuance
10.00
-60.00%
25.00
0.00
0.00
Long Term Debt Payments
-0.08
+3.57%
-0.08
+3.45%
-0.09
+33.59%
-0.13
Net Long Term Debt Issuance
9.92
-60.19%
24.92
+28739.08%
-0.09
+33.59%
-0.13
Net Common Stock Issuance
22.00
+45.66%
15.10
0.00
—
Proceeds From Stock Option Exercised
0.91
+79.57%
0.51
-94.80%
9.79
+10313.83%
0.09
Net Other Financing Charges
-2.07
+20.21%
-2.59
-107.26%
35.74
—
Changes In Cash
11.91
+466.36%
-3.25
-232.03%
2.46
+111.93%
-20.64
Beginning Cash Position
8.88
-26.82%
12.13
+25.49%
9.66
-68.11%
30.30
End Cash Position
20.79
+134.24%
8.88
-26.82%
12.13
+25.49%
9.66
Free Cash Flow
-18.93
+54.04%
-41.19
+19.50%
-51.17
-54.58%
-33.10
Interest Paid Supplemental Data
3.70
+111.26%
1.75
+9622.22%
0.02
0.00
Income Tax Paid Supplemental Data
0.02
-11.11%
0.02
+28.57%
0.01
+55.56%
0.01
Common Stock Issuance
22.00
+45.66%
15.10
0.00
—
Issuance Of Capital Stock
22.00
+45.66%
15.10
+64.37%
9.19
-31.93%
13.50
Net Preferred Stock Issuance
—
0.00
-100.00%
9.19
-31.93%
13.50
Preferred Stock Issuance
—
0.00
-100.00%
9.19
-31.93%
13.50
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category